Future of renal denervation
This video is supported by Medtronic
Summary
It has been a year since the most recent sham controlled trials of renal denervation (RDN) were presented at EuroPCR. Join Felix Mahfoud as he talks to Roland Schmieder and Flavio Ribichini about what they have learned since. Find out what has changed in terms of technology and techniques. Which patients are most likely to choose RDN over additional antihypertensive drug therapy? Find out the crucial role of including patient choice in future trials of RDN and how the results of upcoming pivotal trials may predict which patients will have the best response…
This interview supported by Medtronic was filmed at EuroPCR 2019: see more videos here…